# MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

> **NCT01097460** · PHASE1 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** MM-111 + Herceptin

## Key facts

- **NCT ID:** NCT01097460
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097460, "MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01097460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*